Race Oncology Ltd (ASX: RAC) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Race Oncology Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $223.22 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 173.71 million
Earnings per share -0.084
Dividend per share N/A
Year To Date Return 51.19%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Race Oncology Ltd (ASX: RAC)
    Latest News

    Three rockets heading to space
    Share Gainers

    3 ASX biotech shares rocketing 10% to 26% on BIG news!

    Investors are sending these three ASX biotech stocks flying higher on Thursday.

    Read more »

    A woman stares at a computer with her face just inches from the screen.
    Healthcare Shares

    ASX IPO watch: Aspiring healthcare stock has attracted former Macquarie CEO to invest

    And former federal health minister Greg Hunt is a board director.

    Read more »

    Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
    Healthcare Shares

    2 ASX healthcare shares having a stellar run today

    The ASX healthcare sector is down today but these two stocks are bucking the trend.

    Read more »

    two men smiling with a laptop in front of them, symbolising a rising share price.
    Share Gainers

    Why Pinnacle, PWR, Race Oncology, and Vulcan shares are flying today

    These shares are having a good session on Thursday. But why?

    Read more »

    Shot of a scientist using a computer while conducting research in a laboratory.
    Earnings Results

    Two up, one down: ASX healthcare stocks split after FY24 results

    The love wasn't shared evenly for these healthcare players today.

    Read more »

    Shot of two young scientists using a laptop in a laboratory.
    Healthcare Shares

    2 ASX healthcare shares outperforming on big news

    These two ASX healthcare shares are on the way up on Tuesday after positive news announcements.

    Read more »

    a man in a business suite throws his arms open wide above his head and raises his face with his mouth open in celebration in front of a background of an illuminated board tracking stock market movements.
    Share Gainers

    Why A2 Milk, Actinogen Medical, Karoon Energy, and Race Oncology shares are rising

    These shares are avoiding the market weakness on Wednesday. But why?

    Read more »

    Shot of a young scientist using a digital tablet while working in a lab.
    Healthcare Shares

    Guess which ASX healthcare stock is surging 15% on a 'major milestone'

    What's getting investors excited today? Let's find out.

    Read more »

    Three health professionals at a hospital smile for the camera.
    52-Week Highs

    3 ASX healthcare shares smashing new 52-week highs today

    The buying continues for these healthcare darlings.

    Read more »

    A man sees some good news on his phone and gives a little cheer.
    Share Gainers

    Why Capitol Health, Infratil, Newmont, and Race Oncology shares are charging higher

    These shares are having a good session. But why?

    Read more »

    A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today
    Healthcare Shares

    ASX healthcare stock surges 11% on 'incredibly valuable' FDA news

    Some big news is getting investors excited on Tuesday. What's happening?

    Read more »

    A young women pumps her fists in excitement after seeing some good news on her laptop.
    Share Gainers

    Why Arizona Lithium, Bapcor, Race Oncology, and Tower shares are pushing higher

    These shares are starting the week strongly on Tuesday.

    Read more »

    Frequently Asked Questions

    No, Race Oncology does not pay dividends at this time.

    Sydney-headquartered Race Oncology Ltd listed on the ASX on 13 July 2016.

    RAC ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Race Oncology Ltd

    Race Oncology Ltd (ASX: RAC) is a clinical-stage global biotechnology company focused on cancer care.

    Race’s lead asset, bisantrene, is a small-molecule anthracene chemotherapeutic. It has demonstrated anti-cancer and cardio-protection effects in 46 clinical trials and around 70 peer-reviewed publications.

    The company is now taking its next-generation bisantrene to new fields of cancer treatment. It is initially focusing on two areas of unmet need: metastatic breast cancer (lead indication) and acute myeloid leukaemia (AML).

    As part of its business strategy and clinical program, Race is also investigating the impact bisantrene and new molecules have on the m6A RNA pathway. This follows independent research describing bisantrene as the most potent inhibitor of fat mass and obesity-associated protein (FTO). Dysregulation of RNA (or the over-expression of FTO) has been shown to be a driver of a diverse range of cancers. Race and its partners are now in pre-clinical studies to explore the synergies and impact of bisantrene on FTO regulation.

    RAC Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    04 Dec 2024 $1.29 $-0.02 -1.54% 72,009 $1.32 $1.35 $1.28
    03 Dec 2024 $1.30 $0.03 2.36% 84,931 $1.27 $1.32 $1.26
    02 Dec 2024 $1.27 $-0.06 -4.51% 483,905 $1.35 $1.38 $1.21
    29 Nov 2024 $1.33 $-0.07 -5.02% 69,233 $1.40 $1.40 $1.33
    28 Nov 2024 $1.40 $-0.02 -1.41% 57,678 $1.44 $1.44 $1.36
    27 Nov 2024 $1.42 $0.01 0.71% 89,397 $1.42 $1.42 $1.39
    26 Nov 2024 $1.41 $0.00 0.00% 62,937 $1.43 $1.44 $1.38
    25 Nov 2024 $1.41 $-0.04 -2.76% 49,450 $1.45 $1.45 $1.41
    22 Nov 2024 $1.45 $0.02 1.40% 89,583 $1.41 $1.45 $1.40
    21 Nov 2024 $1.43 $0.07 5.15% 112,377 $1.42 $1.44 $1.39
    20 Nov 2024 $1.36 $-0.03 -2.15% 60,360 $1.40 $1.40 $1.36
    19 Nov 2024 $1.40 $-0.05 -3.45% 155,510 $1.45 $1.45 $1.33
    18 Nov 2024 $1.45 $0.00 0.00% 185,413 $1.45 $1.45 $1.35
    15 Nov 2024 $1.45 $0.03 2.11% 115,365 $1.43 $1.45 $1.40
    14 Nov 2024 $1.42 $-0.05 -3.41% 164,460 $1.49 $1.49 $1.41
    13 Nov 2024 $1.47 $0.00 0.00% 87,737 $1.48 $1.50 $1.46
    12 Nov 2024 $1.47 $-0.05 -3.28% 96,366 $1.53 $1.58 $1.46
    11 Nov 2024 $1.53 $-0.05 -3.17% 113,098 $1.58 $1.59 $1.51
    08 Nov 2024 $1.58 $0.05 3.29% 67,130 $1.56 $1.61 $1.56
    07 Nov 2024 $1.52 $-0.12 -7.34% 104,838 $1.62 $1.63 $1.52
    06 Nov 2024 $1.64 $0.05 3.15% 60,865 $1.58 $1.65 $1.57
    05 Nov 2024 $1.59 $0.03 1.94% 159,815 $1.54 $1.59 $1.53

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    26 Nov 2024 Serge Scrofani Issued 58,446 $82,408
    Issue of options.
    30 May 2024 Mary Harney Exercise 1,170 $877
    Exercise of options.
    30 May 2024 Mary Harney Issued 3,510 $5,036
    Issue of options.
    30 May 2024 Mary Harney Issued 1,170 $877
    Exercise of options.
    23 May 2024 Phillip(Phil) Lynch Issued 21,457 $16,092
    Exercise of options.
    23 May 2024 Phillip(Phil) Lynch Exercise 21,457 $16,092
    Exercise of options.
    23 May 2024 Phillip(Phil) Lynch Issued 64,371 $93,659
    Issue of options.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Dr Daniel Tillett Chief Executive OfficerManaging Director Sep 2019
    Dr Tillett is the CEO and founder of Nucleics Pty Ltd, a private biotechnology company in the genomics space. He was previously a Senior Lecturer within the School of Pharmacy at La Trobe University where he lectured on biochemistry, biotechnology, pharmacy, microbiology and virology.
    Dr Peter (Pete) Smith Executive DirectorExecutive Chairman Jun 2023
    Dr Smith has over 35 years of experience in the pharmaceutical and biotech industry, with a focus on therapeutics, especially oncology. He has been involved in projects at all stages from concept to phase III clinical studies. He was previously the CEO of private biotechnology company Myrio Therapeutics, and publicly listed Australian companies Alchemia and AMRAD. Prior to moving to Australia, Dr Smith co-founded and was CFO of Onyvax Ltd, a cancer immunotherapy company based in London. At the start of his career, he was a Pharmaceuticals Analyst with UBS and HSBC, being involved in transactions including LSE/NASDAQ initial public offerings, fundraisings, and mergers & acquisitions (M&A). He is also currently a Director of MycRx Inc. and Amala Therapeutics.
    Dr Serge Scrofani Non-Executive Director Sep 2024
    Dr Scrofani has more than 28 years experience in the healthcare sector, working in global roles across research, strategy and corporate development. He served as Vice President of Strategy & Corporate Development at CSL for 13 years where he played a role in multiple strategic initiatives. Prior to this, he led Business Development for CSL Behring based in the US. Serge is currently Principal of Poplar Advisory, a boutique strategic advisory firm focused on the healthcare sector. He is also a Board member of the Burnet Institute and The Centre for Eye Research, and a founding Director of the private equity firm FinCap Pty Ltd.
    Mr Peter Webse Company Secretary Aug 2016
    -
    Michelle Rashford Chief Medical Officer
    -
    Peter Webse Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Dr Daniel Tillett 17,267,615 10.13%
    Mr Phillip Richard Perry 6,334,328 3.72%
    Mr Mark Phillip Juan 5,839,062 3.43%
    The Trust Company (Australia) Limited <Mof A/C> 5,147,246 3.02%
    Biosynergy Partners Pty Ltd 4,855,700 2.85%
    BNP Paribas Nominees Pty Ltd <IB AU Noms Retailclient > 2,618,464 1.54%
    Marinella Messina 1,845,245 1.08%
    Mr Phillip Richard Perry & Mrs Tetyana Perry <Doneska Super Fund A/C> 1,669,500 0.98%
    Mr Sandor Helby 1,625,000 0.95%
    Mr Kimberley Ross Gartrell & Mrs Jennifer Margaret Gartrell <K&J Gartrell Super Fund A/C> 1,575,000 0.92%
    Kudoss Investments Pty Ltd <Aitken Global Family A/C> 1,500,000 0.88%
    Mr Anthony James Robinson <The Peeko Family No 86 A/C> 1,370,262 0.80%
    Mr Alan Giles Sauran 1,094,368 0.64%
    Mr Brian James Walker 955,000 0.56%
    Pierpont Investments Pty Ltd <Pierpont Super Fund A/C> 950,000 0.56%
    Surpion Pty Ltd <M W Suhr & Co A/C> 935,000 0.55%
    Citicorp Nominees Pty Limited 847,284 0.50%
    Mr Van Quy Do 829,409 0.49%
    Mr Beau Thomas Robinson <Beau Robinson Invstmnt A/C> 743,458 0.44%
    Mr Graeme Stewart Pocknall & Mrs Vivienne Glynis Pocknall 674,511 0.40%

    Profile

    since

    Note